China admits foreign capital by degrees rather than all at once. Foreign direct investment in China works inside a framework that has opened one sector after another while holding on to its industry caps, its licensing requirements and its screening of deals. For anyone weighing a PRC project, two instruments are decisive. One is the negative list governing access; the other, the Foreign Investment Law of the People's Republic of China, or FIL. Licensing and registration come first, while reporting continues for as long as the entity exists.
Below I set out the forms inbound capital can take here, and the sectors that remain closed or capped. From there: how a company reaches the market, what it must report afterward, and which transactions draw screening.
The framework behind inbound capital
Beijing opens the domestic market in stages, and pairs investment promotion with control over access to particular industries. Supplying the frame for that control is the FIL itself. Regulations made under it fill in how it applies in practice, and a separate body of admission rules governs entry itself.
The regime governing foreign investment in China rests on two mechanisms working together. Overseas investors are granted national treatment; the negative list then carves out every exception to it.
Where an activity falls outside the list in force, an overseas investor operates on terms broadly equivalent to those available to Chinese capital. A listed activity meets restrictions on the foreign share, or an outright ban, so anyone planning an inbound project begins with eligibility and only afterward with structure. Is inbound investment permitted at all in the industry concerned? Does the project trigger special licensing requirements? Do further conditions govern its admission to the market? No structuring decision survives a negative answer to any of the three.
Five investment routes, WFOE registration and joint ventures among them
Project goals, the ownership arrangement and the nature of the business together determine the form of presence. Five routes stand open to an inbound investor.
- buying shares, or equity interests, in a local company;
- taking over particular assets of Chinese enterprises, in whatever cases and by whatever route the law lays down;
- increasing the registered capital of an existing Chinese enterprise;
- forming a venture jointly with a local partner;
- and, last, establishing a mainland company funded with foreign capital.
All five produce the same vehicle: the foreign-invested enterprise, or FIE, a registered Chinese legal entity free to trade and to operate once it satisfies what its activity demands. Two variants of it exist, and which of the two an investor adopts depends on a single question: does a local partner hold equity or not?
Where no local partner takes a stake, the vehicle is a wholly foreign-owned enterprise, or WFOE. WFOE registration lets an overseas investor hold 100% of the equity across a broad span of industries, so the business is controlled without a domestic partner. Manufacturers and traders adopt it as readily as service companies do, subject always to the admission and licenses their particular activity requires, and the form serves other activities in the same way.
Where a Chinese investor holds some of the equity, the vehicle is a joint venture instead. That structure is preferable where the local side adds genuine commercial value, and it becomes unavoidable where the sector's rules limit foreign capital.
Closed, capped, open: reading the China foreign investment negative list
One instrument governs market access. Its formal title reads Special Administrative Measures for Foreign Investment Access. In practice it is known as the Foreign Investment Negative List, shortened here to the FI Negative List. Its edition of 2024 sets out which industries and activities attract special restrictions and which face an outright ban on capital from abroad.
Whatever the sector concerned, an entry on the China foreign investment negative list restricts access in one of six distinct ways.
- mandatory participation of Chinese investors or partners;
- qualification requirements for managers and key specialists;
- a ceiling on the share of capital held from abroad;
- a narrowing of what the business may actually do;
- the ownership and corporate-control structures permitted;
- other special conditions of admission into the industry concerned.
Outright prohibition applies to several strategic and regulated sectors. Everywhere else on that list, admission is limited rather than barred: an applicant may proceed on the conditions the law lays down. Beyond the list, national treatment takes over: meet the general statutory requirements and an investor enters on terms comparable to those of Chinese market participants.
Six regulatory sources and what each determines
The regulatory review precedes everything else: company registration in China depends on it, as does the purchase of an existing Chinese business, and as does any commitment of capital to a project. Six separate sources supply the answer between them, and none of the six can safely be skipped.
|
Source |
What it determines |
|
Sectoral legislation and special regulations |
the substantive rules for the industry |
|
FI Negative List |
what is barred to foreign capital, and what is merely capped |
|
Admission rules for regulated activities |
who may carry on the activity at all |
|
Market Access Negative List (MA Negative List) |
general limits on economic activity, whatever the investor's origin |
|
Provincial, municipal and free trade zone rules |
local conditions in territories with a special regime |
|
License and permit requirements |
which authorizing documents the business needs |
The MA Negative List carries considerable weight: it binds Chinese and overseas capital alike, and its 2025 edition brought the restrictive items down to 106 from the earlier 117. Since the two lists run independently of one another, an activity can pass the first and still be caught by the second. Both checks are therefore run concurrently.
Manufacturing after the 2024 liberalization
Liberalization has gone furthest in manufacturing. In 2024 Beijing lifted the national-level curbs that had bound overseas capital there, which widened the field considerably for companies weighing a Chinese plant, a localization program or a manufacturing joint venture in China.
Sector access is distinct from project approval. What a given venture still needs depends on what it does, on the site, on the technology and on the potential environmental impact. Before production starts, an investor works through a further set of requirements.
- industrial and fire safety;
- land use;
- urban planning and conformity with the site's designated use;
- environmental permits;
- construction and reconstruction permits;
- registration and recording of production facilities;
- sectoral licensing.
Registration, and formal admission of overseas capital into an industry, take a venture only through its opening stage. Separate verification then applies to the sectoral and administrative conditions; to licensing; to environmental clearance; and to land and planning conformity.
Due diligence before the investment has nine points at a minimum.
- the intended type of business activity;
- its position on the FI Negative List;
- its standing under the MA Negative List;
- any licensing requirement;
- sectoral requirements;
- the permitted structure of foreign participation;
- corporate-control requirements;
- environmental and other mandatory approvals;
- land, construction and the siting of production facilities.
Encouraged industries under the Catalogue
The prohibitions have a counterpart that works by incentive rather than restriction.
Its counterpart is the Catalogue of Industries for Encouraging Foreign Investment, whose current edition runs to 1,679 entries and sets out which sectors the authorities actively encourage. Seven areas of activity carry that priority:
- research and development work;
- advanced and high-technology manufacturing;
- energy saving, together with environmental protection and green technology;
- professional services;
- innovative projects;
- selected projects placed in the PRC's central or western provinces;
- other directions matching state industrial and investment policy.
Encouraged status under the Catalogue exempts a project from nothing, and every requirement set out above still binds foreign investment in China exactly as before. Depending on what it does, such a project may still have to complete every formalization procedure its own activity calls for. The investor may also have to put the company on the register and collect every permit the business needs. Currency control applies to it as to any other company, and so do tax accounting, corporate governance and whatever else the applicable PRC framework imposes. Planning therefore starts by fixing the project's sectoral classification, tests it against the Catalogue, and finishes by confirming that the Negative List does not catch the activity.
Contact our specialists
Seven stages of China market entry
Market entry through foreign direct investment requires preparation on four fronts at once: legal, corporate, tax and regulatory. China market entry breaks into seven stages.
Legal and regulatory analysis of the planned activity comes first. The investor establishes whether the industry admits foreign capital at all, and what special restrictions attach to it; the analysis then turns to whichever edition of the FI Negative List is in force. A second instrument is reviewed concurrently. The MA Negative List defines which activities need special permission, and which stay restricted no matter where the investor comes from.
Stage one also assesses a second group of questions.
- qualification requirements for participants and managers;
- restrictions applying specifically to overseas investors;
- the permitted volume of foreign participation, and its form;
- special sectoral permits;
- licensing requirements;
- the regulatory particularities of the sector;
- data protection and cybersecurity requirements;
- any limits on moving data out of the country.
The form of presence follows from the industry, from the investment strategy and from the degree of control the investor wants; corporate governance weighs in as well, alongside the tax model and any special permits. For many investors the question reduces to WFOE or joint venture. Full corporate control stays with the investor in a WFOE. A joint venture is the better choice when the project needs what a partner on the Chinese side contributes: local expertise, business connections, production capacity or other resources.
Due diligence precedes the investment itself, and a detailed reading of the applicable inbound investment rules goes with it. Where the plan is to buy a Chinese target outright or a stake in one, the review covers the target's legal status, its ownership arrangements and the whole of its corporate documentation. Licenses and contracts follow, then assets and liabilities. Litigation, tax exposure and any other encumbrances close the list.
Certain deals need more than that.
- sectoral licenses and administrative permits;
- cybersecurity law;
- personal data protection law;
- limits on moving data out of the country;
- antitrust requirements;
- the requirements applying to investment in strategic or regulated industries.
One question dominates the stage. The parties establish whether prior approval, notification or permission of state authorities must be obtained before closing or before the activity begins.
Once the structure is fixed, the parties assemble the document package for establishing or buying the business, while a joint venture brings one further negotiation on top of all of that. The Chinese partner's participation terms are agreed between the shareholders, and so is the way rights and obligations divide. Corporate decision-making and profit distribution are settled in that same negotiation, together with financing and the exit mechanisms. Drafting covers the investment documents and the articles of association alike. Corporate resolutions and the agreements between the participants themselves belong to that same package, along with whatever else registration and the operation that follows it require.
With the documents ready, the Chinese entity itself is formalized in the prescribed manner. Registration alone confers no automatic right to carry on commercial activity of any kind, and where the business needs special licenses or administrative permits, those are obtained separately from the registration itself.
The state reporting system records three matters: who the investor is, how ownership is arranged, and what the investment does. Filing and updating duties arise twice over: on incorporation, and on any change to material corporate information.
A regulated sector requires more than registration, and the investor collects its permits and administrative approvals afterward, or in whatever order the law prescribes. FDI regimes differ from one industry to the next. Additional licensing applies in finance and telecommunications, for instance, and again in education and healthcare. Manufacturing, food production and logistics impose conditions of their own as well.
A regulatory licensing map is worth building before entry, since it sets out every mandatory permit and notification the business needs. Compliance with PRC law continues for as long as the business trades. Corporate and registration records need updating on time. On a change of director or of legal representative the company must then amend its entries on the state registers and notify every authority concerned. A change of address, of participants, of capital or of business scope has the same effect.
What an FIE has to report, and when
For an FIE, disclosure begins at incorporation and continues throughout: whenever corporate or investment data change, the file is updated. Four kinds of report exist for a foreign-invested enterprise.
|
Report |
When it is due |
|
Initial report |
on establishing a company with foreign capital |
|
Change report |
when reportable information changes |
|
Annual report |
within the annual reporting cycle |
|
Cessation or liquidation information |
where the applicable rules require it |
Timing depends on whichever procedure the investor is already in. Opening the company normally carries the initial report along with it, while acquiring a stake in an operating enterprise puts the disclosure inside the corporate-change formalities instead.
Updates follow that same logic. An update that also touches the state register travels with that filing, while anything outside state registration goes in on its own, normally within 20 working days of the date the circumstances arise.
The annual corporate return stands apart from all of this. A company files it through the National Enterprise Credit Information Publicity System. Its window is fixed: it opens on 1 January and closes on 30 June, in the year after the period reported. Where incorporation falls within the current calendar year, the first of these returns only becomes due one full cycle later.
Accuracy is essential in these filings. Whatever a company submits must match the corporate register and the actual state of the business at the time of filing. An error, an omission or a late filing brings correction afterward, plus whatever other consequences the law attaches. From 1 July 2026 a separate correction procedure applies to overdue, erroneous or incomplete annual filings.
National-security screening, and what that means for M&A
Sector access does not put a transaction beyond further scrutiny. Inbound capital is also screened on national-security grounds; foreign investment in China is reviewed one transaction at a time. The foreign investment security review reaches four categories of deal in particular. A new or joint enterprise founded inside the PRC falls within it, and so does any purchase of shares, or of equity, in a Chinese target. So does an acquisition of particular business assets, and so does investment in industries counted as sensitive.
M&A deserves the closest attention here. Acquiring an operating Chinese company, or a stake in its capital, or particular business assets, meets several regimes at once. Before signing, the buyer checks regulatory restrictions and mandatory approvals in full, and these nine points in particular.
- whether a sectoral license or a prior administrative permit is needed;
- whether the target's own activity is caught by the list;
- whether an antitrust notification duty arises;
- whether a cap binds the foreign share, or requirements attach to ownership structure;
- whether a security review reaches the deal;
- whether the company must amend its entry at the state registry;
- whether PRC rules on data, on transfers abroad and on cybersecurity catch it;
- whether limits attach to moving particular assets, technologies, personal data or other regulated information;
- whether a change of ownership structure or of the controlling person calls for further approvals.
What the June 2026 action plan sets out
In June 2026 Beijing published an action plan whose whole subject is foreign investment in China. The plan's stated purpose is to hold foreign capital steady and to raise its quality, which in practice means wider market access, easier day-to-day business and better conditions for corporate presence over the long run. It replaces nothing in the binding architecture. Registration and reporting procedures stand exactly as before; nothing has changed on the negative list, and the FIL stands where it stood.
The services sector leads on access. Pilot programs opening vocational skills training bodies and vocational-technical education to capital from abroad are set to expand. The same holds for certain fields of higher education in natural sciences and engineering, in agriculture and in medicine. Economic cooperation deepens with Hong Kong and with Macao, and investors from both are to reach the services sector on priority-opening terms.
Finance opens further while the regulatory and risk-management requirements stay. Foreign financial institutions are to gain the use of risk-management instruments including government bond futures, and foreign firms are to develop fund investment advisory work. Large foreign companies should find cross-border financing easier and international settlement services from Chinese banks better, and organizations weighing a domestic share listing are promised improved preliminary engagement.
Pharmaceuticals and medicine have a package of their own. For a foreign marketing authorization holder manufacturing biological and chemical medicinal products in stages across borders, conditions are to be simplified. The authorities will also study extending the regions whose pilots reach biotechnology and medical institutions owned entirely from abroad. For an international pharmaceutical or medical group, that opens further scope to localize production and widen its presence.
M&A rules come next in the plan, and they are due for rewriting. Revision and adoption of the rules governing acquisitions of PRC enterprises, where the buyer is an overseas investor, are to accelerate. Procedures and settlement requirements are to be optimized, and the authorities that review such deals are to work more closely together.
The movement of data across borders forms a fourth strand. Free economic zones and pilot service-sector cities are to receive support in drawing up their own transfer lists for data leaving the country, one use case at a time and split by data type. Standards defining important data are to follow at national level, and the industries named cover manufacturing and telecommunications; geographic information and automotive; pharmaceuticals and seed breeding; aerospace and civil aviation. This strand of the plan matters particularly to a group moving data between its mainland subsidiary and a head office abroad.
Reinvested profit attracts tax incentives. Investors who channel distributed profit back into the mainland economy stand to benefit from them. More reinvestments by overseas enterprises are also to be admitted to the registers of major and priority investment projects, and admission there widens the state support on offer to them. A local subsidiary can accordingly serve as the platform for further expansion on the mainland.
International R&D centers are a priority in themselves. Support for foreign research centers should improve, recruiting highly qualified specialists from abroad should become easier, and backing is promised for new formats of research organization and for open innovation platforms. Commercialization of research results is supported, and statutory tax relief extends to research equipment and materials brought in from abroad.
What the changes mean for an inbound investor
More sectors keep opening, and every foreign-invested enterprise already inside sees its operating conditions improve. An investor has to work on two levels at once. One of them binds outright. That level covers the FIL and the Negative List, together with market-access rules and the statutory reporting obligations of the company. Discretionary support from the state makes up the other. That support is aimed at manufacturing and R&D, at pharmaceuticals, at the digital economy and at profit put back in.
Keeping the two apart matters, because the legal weight attaching to each of them differs: certain measures operate today, while others describe mechanisms that have still to be built or widened. A project named in a state plan is guaranteed no benefit and no shortcut. What any one investor receives will reflect the industry and the region, the shape of the project, and whichever rules are in force when it is carried out.
Conclusion: where this leaves an investor
Two forces operate alongside each other here. One opens industries a few at a time. The other holds on to the special requirements, and with them the state's own control over who enters the market. Any investor considering an inbound project must assess both before committing capital. Is the activity admissible, and what corporate structure fits it? Then come licensing and reporting, cross-border operations and screening. Real opportunity lies in the priority areas the state has named. Manufacturing is among them, and R&D, and reinvested profit alongside pharmaceuticals and modern services.
I provide end-to-end legal support for foreign direct investment in China, from an early assessment of the regulatory requirements through to risk reduction and compliance with PRC law.